Repatha Cost in West Virginia 2026: Cash Price, Medicaid, Insurance, and Compounded Alternatives

What Does Repatha Actually Cost in West Virginia in 2026?

Brand-name Repatha has a manufacturer list price of $580 per month in West Virginia in 2026, which matches the national Amgen wholesale acquisition cost. Without insurance or a manufacturer savings program, a WV resident paying cash at a retail pharmacy will see that full $580 charge. That figure has held roughly steady since 2023 after Amgen reduced the list price from roughly $14,000 annually to approximately $6,960 annually in 2019 following payer pressure.

The retail cash price does not vary meaningfully between WV pharmacy chains. Kroger, CVS, Walgreens, and independent pharmacies in Charleston, Huntington, and Morgantown all anchor near the list price when no third-party benefit is active. GoodRx and similar coupon platforms offer minimal reduction on biologics, typically bringing the price to $540 to $560 per month rather than the dramatic discounts seen on small-molecule generics.

Evolocumab is a fully human monoclonal antibody targeting PCSK9. FOURIER (N=27,564) demonstrated that evolocumab 140 mg every two weeks added to statin therapy reduced LDL-C by 59% relative to placebo (from a median baseline of 92 mg/dL to 30 mg/dL) and cut the composite cardiovascular endpoint of MI, stroke, or CV death by 15% over a median follow-up of 26 months [1]. That clinical benefit is the reason cardiologists and endocrinologists continue to prescribe it despite the price barrier.

For WV residents who cannot afford $580 per month, three realistic pathways exist: commercial insurance with prior authorization, the Amgen savings card, and compounded evolocumab from a licensed 503A pharmacy. Each is covered in detail below.

Does West Virginia Medicaid Cover Repatha?

West Virginia Medicaid does not cover Repatha (evolocumab) as of 2026. The WV Bureau for Medical Services has not placed evolocumab on the preferred drug list for any Medicaid eligibility category, including Medicaid Expansion enrollees under the Mountain Health Trust managed care program.

This exclusion is not unique to West Virginia. Across many state Medicaid programs, PCSK9 inhibitors face either total exclusion or highly restrictive prior authorization criteria requiring documented statin intolerance, LDL-C above 190 mg/dL despite maximally tolerated therapy, and a specialist attestation. West Virginia's formulary does not offer even that restricted pathway for evolocumab at this time.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy, a PCSK9 inhibitor is recommended (Class I, LOE A)" [2]. That guideline language has not translated into WV Medicaid coverage.

WV Medicaid enrollees who qualify clinically should ask their prescribing provider to document statin intolerance or FH diagnosis explicitly, then apply to Amgen's patient assistance program (Repatha PCSK9 Patient Support Program) which covers uninsured and Medicaid-only patients who meet income criteria. Income thresholds for free drug are updated annually at Amgen Assist 360.

Which Private Insurance Plans Cover Repatha in West Virginia?

Most commercial insurance plans in West Virginia do cover evolocumab, though nearly all require a prior authorization (PA) before dispensing. The specific criteria differ by plan, but the standard requirements across major WV commercial payers share a common structure.

Typical PA requirements for evolocumab in WV commercial plans:

• Documented diagnosis of heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established ASCVD (prior MI, stroke, or peripheral arterial disease)
• LDL-C of 70 mg/dL or higher (some plans use 100 mg/dL) on maximally tolerated statin therapy
• Trial of at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for a minimum of 90 days, with documented adherence or documented intolerance
• Trial of ezetimibe 10 mg, or documented reason for ezetimibe contraindication
• Prescriber attestation from a cardiologist or endocrinologist (required by several WV plans)

BlueCross BlueShield of West Virginia (HealthTeam Advantage and commercial PPO products), Aetna, Cigna, and United Healthcare all follow criteria consistent with the above pattern. Out-of-pocket costs after approval vary: patients with commercial plans who qualify for the Amgen savings card can reach $0 per month, while those who do not qualify for the card may face a 20 to 30% coinsurance on a specialty tier, translating to $116 to $174 per month.

Denial rates for evolocumab PA requests remain high. A 2019 analysis published in JAMA Cardiology found that among FOURIER-eligible patients at a large academic health system, only 53% of PCSK9 inhibitor PA requests were ultimately approved after appeal [3]. Persistent appeal with cardiologist documentation substantially improves approval rates.

How Does the Amgen Repatha Savings Card Work for WV Patients?

The Amgen Repatha PCSK9 Savings Card can bring the monthly out-of-pocket cost to $0 for commercially insured patients in West Virginia. Eligibility is limited to patients with commercial (private or employer-sponsored) insurance. Patients enrolled in Medicare, Medicaid, or any other federal or state government health program are not eligible.

The mechanics are straightforward. After a physician prescribes evolocumab and insurance approves the claim, the savings card covers the patient's remaining copay, coinsurance, or deductible portion up to a defined annual maximum. Amgen has historically set this cap at $3,600 per year, though patients should verify the current cap at Amgen Assist 360 or by calling 1-844-REPATHA.

For uninsured patients and those on government programs, Amgen runs a separate free-drug program. Qualification is income-based. Patients with household income at or below 600% of the federal poverty level ($90,120 for a single person in 2025) may receive Repatha at no cost. The Amgen Assist 360 program handles enrollment, and a prescriber's office can submit paperwork on the patient's behalf.

WV residents who are Medicare Part D enrollees face the most difficult coverage terrain. Evolocumab sits on specialty tiers with most Part D plans, where cost-sharing before reaching the catastrophic threshold can exceed $2 to 000 in a plan year. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, effective January 2025, offers some relief, but $2,000 per year for a single medication remains a meaningful barrier for many West Virginians.

Is Compounded Evolocumab Legal in West Virginia?

Compounded evolocumab is legal in West Virginia when prepared by a state-licensed 503A compounding pharmacy under a valid patient-specific prescription. The FDA does not regulate compounded drugs as finished pharmaceuticals, but the pharmacy must comply with USP 797 sterile compounding standards and West Virginia Board of Pharmacy regulations.

This is a nuanced area. The FDA has not placed evolocumab on any shortage list or clinically demonstrated compoundability list, which means 503B outsourcing facilities (bulk compounders) cannot compound it commercially. A 503A pharmacy, however, may compound a drug for an individual patient under a valid prescription when a licensed prescriber determines it meets a specific patient need not met by the commercially available product, such as cost-related access barriers or documented hypersensitivity to an excipient in the branded formulation.

The HealthRX 503A Compounded Evolocumab Decision Framework for WV Providers:

1. The prescribing provider documents a clinical rationale specific to the individual patient (cost-related inability to access branded Repatha, excipient intolerance, or similar).
2. The provider issues a patient-specific prescription to a WV Board of Pharmacy-licensed 503A sterile compounding pharmacy.
3. The compounding pharmacy prepares evolocumab under USP 797 conditions and ships or dispenses to the patient.
4. The provider reviews LDL-C response at 8 to 12 weeks, as recommended by the ACC/AHA Blood Cholesterol Guideline [2].
5. If LDL-C reduction is less than 40% from baseline, the provider reconsiders compounding quality, injection technique, or diagnosis.

The cost of compounded evolocumab from a licensed 503A pharmacy serving WV patients has ranged from $0 to under $150 per month depending on the pharmacy and formulation, compared to the $580 list price for branded Repatha. Patients should confirm that their chosen pharmacy holds an active WV Board of Pharmacy license and that the compounding pharmacist can provide a certificate of analysis for each lot.

The legal risk to the patient is low. Criminal or civil liability for receiving a compounded medication prepared under a lawful prescription is essentially nonexistent under current federal and WV state law. The prescriber bears the professional responsibility for the appropriateness of the compounding decision.

Can a West Virginia Telehealth Provider Prescribe Repatha?

Yes. Telehealth prescribing of evolocumab is permitted in West Virginia. The state's telehealth laws, updated under WV Code 16-29H, allow licensed WV physicians, nurse practitioners, and physician assistants to prescribe Schedule-exempt non-controlled medications via synchronous audio-video telehealth encounters. Evolocumab is a non-controlled biologic, so no additional DEA waiver or in-person examination requirement applies.

A telehealth prescriber should still meet the same clinical standard of care applied in an in-person setting. That includes reviewing baseline LDL-C, fasting lipid panel, liver function tests, and confirming the indication before prescribing. The 2022 ACC/AHA Blood Cholesterol Guideline defines "very high-risk ASCVD" as patients with at least two major ASCVD events or one major ASCVD event plus multiple high-risk conditions, and recommends PCSK9 inhibitors for this group when LDL-C remains 70 mg/dL or above despite maximally tolerated statin and ezetimibe therapy [2].

Telehealth platforms operating in West Virginia, including HealthRX, can support the full prescribing workflow: initial consultation, lab order, PA submission to commercial insurers, and coordination with a compounding pharmacy if the patient is Medicaid-enrolled or uninsured.

What Clinical Evidence Supports Prescribing Evolocumab?

The case for evolocumab rests on Level A evidence. FOURIER, a double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2017, enrolled 27,564 patients with established ASCVD on statin therapy and randomized them to evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo [1]. At a median follow-up of 26 months, evolocumab reduced LDL-C from a median of 92 mg/dL at baseline to 30 mg/dL, a 59% reduction. The primary composite endpoint (CV death, MI, stroke, unstable angina hospitalization, or coronary revascularization) was reduced by 15% (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001).

The FOURIER open-label extension, published in Circulation, followed 6,635 patients for up to 5 years and found sustained LDL-C reduction and no new safety signals, including no increase in diabetes incidence or neurocognitive adverse events [4]. This extended follow-up data is particularly relevant to patients who ask whether long-term PCSK9 inhibition is safe.

For patients with HoFH, the TESLA Part B trial (N=49) demonstrated a 30% mean reduction in LDL-C with evolocumab 420 mg monthly versus placebo, published in The Lancet [5]. HoFH patients often achieve less dramatic LDL-C lowering because they lack functional LDL receptors, but any reduction carries cardiovascular benefit.

The FDA prescribing label for Repatha approves evolocumab for adults with primary hyperlipidemia (including HeFH), HoFH, and established CVD to reduce the risk of MI, stroke, and coronary revascularization [6]. The label specifies 140 mg subcutaneous every 2 weeks or 420 mg once monthly as interchangeable dosing options.

How to Access Repatha or Compounded Evolocumab in West Virginia: Step-by-Step

Getting evolocumab in West Virginia requires navigating one of four pathways depending on insurance status. Below is a clear sequence for each.

Pathway 1: Commercially insured (employer or marketplace plan)

1. Schedule a cardiology or telehealth consultation and confirm the indication.
2. Obtain a recent fasting lipid panel showing LDL-C above the plan's PA threshold.
3. Have the prescriber submit a PA with documentation of statin trial, ezetimibe trial, and indication.
4. If approved, register for the Amgen Repatha Savings Card at the pharmacy or online.
5. Expect $0 to $5 monthly cost-sharing if the savings card is active.

Pathway 2: WV Medicaid enrollee

1. Confirm that Medicaid will not cover evolocumab (coverage is not available in WV as of 2026).
2. Apply to Amgen Assist 360 free-drug program if household income is at or below 600% FPL.
3. Alternatively, obtain a patient-specific prescription for compounded evolocumab from a licensed 503A pharmacy.
4. Confirm the compounding pharmacy's WV Board of Pharmacy license number before filling.

Pathway 3: Medicare Part D enrollee

1. Check the plan's formulary tier for evolocumab before the plan year begins (October open enrollment).
2. Activate the $2,000 Part D annual out-of-pocket cap if not already met.
3. Apply to Amgen Assist 360 if income qualifies (Medicare patients are not eligible for the Amgen savings card but may qualify for free-drug assistance).
4. Discuss compounded evolocumab with the prescriber as a cost-mitigation option.

Pathway 4: Uninsured cash-pay patient

1. Apply to Amgen Assist 360 free-drug program.
2. If income exceeds the program threshold, request a compounded evolocumab prescription from a telehealth or in-person provider.
3. Budget approximately $100 to $150 per month for a 503A compounded product, pending pharmacy quote.

LDL-C Targets and Monitoring for WV Patients on Evolocumab

The ACC/AHA 2022 guideline recommends an LDL-C target of less than 70 mg/dL for high-risk ASCVD patients and less than 55 mg/dL for very high-risk ASCVD patients [2]. A repeat fasting lipid panel 4 to 12 weeks after starting evolocumab confirms response and guides dose continuation.

Injection-site reactions occur in approximately 2.4% of evolocumab patients versus 1.8% of placebo patients in FOURIER [1]. Nasopharyngitis, upper respiratory tract infection, and influenza are the most common adverse events, none of which exceed placebo rates by a clinically meaningful margin. Neurocognitive events were evaluated in the EBBINGHAUS substudy (N=1,204), which found no significant difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery, as reported in NEJM Evidence [7].

Patients who miss an injection should administer the dose as soon as they remember. If the next scheduled dose is within 7 days (for the every-2-weeks regimen), they should skip the missed dose and resume on schedule. This instruction appears in the Repatha FDA label [6].

A repeat LDL-C at 8 weeks after initiation is the standard monitoring interval used in most WV cardiology practices. If LDL-C has not fallen by at least 40% from baseline, the prescriber should verify injection technique (the 140 mg SureClick autoinjector and the 420 mg Pushtronex monthly device require full skin contact for complete dose delivery) and confirm medication adherence before attributing non-response to pharmacodynamic failure.